Education
About Us
Working with TipRanks
Follow Us
Paradigm Biopharmaceuticals Ltd. (AU:PAR)
ASX:PAR
Total Valuation
Paradigm Biopharmaceuticals has a market cap or net worth of $179.99M. The enterprise value is AU$101.96M.
Market Cap$179.99M
Enterprise ValueAU$101.96M
Share Statistics
Paradigm Biopharmaceuticals has 423,511,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding423,511,540
Owned by Insiders4.89%
Owned by Institutions<0.01%
Financial Efficiency
Paradigm Biopharmaceuticals’s return on equity (ROE) is -0.89 and return on invested capital (ROIC) is -79.54%.
Return on Equity (ROE)-0.89
Return on Assets (ROA)-0.76
Return on Invested Capital (ROIC)-79.54%
Return on Capital Employed (ROCE)-1.07
Revenue Per Employee10.00T>
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Paradigm Biopharmaceuticals is ―. Paradigm Biopharmaceuticals’s PEG ratio is 0.07.
PE Ratio―
PS Ratio1840.42
PB Ratio4.53
Price to Fair Value4.53
Price to FCF-6.00
Price to Operating Cash Flow-5.13
PEG Ratio0.07
Income Statement
In the last 12 months, Paradigm Biopharmaceuticals had revenue of 52.12K and earned -18.77M in profits. Earnings per share was -0.06.
Revenue52.12K
Gross Profit-19.89K
Operating Income-22.89M
Pretax Income-25.30M
Net Income-18.77M
EBITDA-25.25M
Earnings Per Share (EPS)-0.06
Cash Flow
In the last 12 months, operating cash flow was -15.99M and capital expenditures 3.00, giving a free cash flow of -15.99M billion.
Operating Cash Flow-15.99M
Free Cash Flow-15.99M
Free Cash Flow per Share-0.04
Dividends & Yields
Paradigm Biopharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.14
52-Week Price Change102.38%
50-Day Moving Average0.33
200-Day Moving Average0.37
Relative Strength Index (RSI)61.71
Average Volume (3m)1.50M
Important Dates
Paradigm Biopharmaceuticals upcoming earnings date is Feb 25, 2026, TBA (Confirmed).
Last Earnings DateAug 29, 2025
Next Earnings DateFeb 25, 2026
Ex-Dividend Date―
Financial Position
Paradigm Biopharmaceuticals as a current ratio of 7.46, with Debt / Equity ratio of 0.53%
Current Ratio7.46
Quick Ratio7.46
Debt to Market Cap<0.01
Net Debt to EBITDA0.67
Interest Coverage Ratio-3.23K
Taxes
In the past 12 months, Paradigm Biopharmaceuticals has paid -6.53M in taxes.
Income Tax-6.53M
Effective Tax Rate0.26
Enterprise Valuation
Paradigm Biopharmaceuticals EV to EBITDA ratio is -3.13, with an EV/FCF ratio of -4.95.
EV to Sales1.52K
EV to EBITDA-3.13
EV to Free Cash Flow-4.95
EV to Operating Cash Flow-4.95
Balance Sheet
Paradigm Biopharmaceuticals has $16.82M in cash and marketable securities with $5.48K in debt, giving a net cash position of $16.81M billion.
Cash & Marketable Securities$16.82M
Total Debt$5.48K
Net Cash$16.81M
Net Cash Per Share$0.04
Tangible Book Value Per Share$0.07
Margins
Gross margin is -13.34%, with operating margin of -43910.60%, and net profit margin of -36014.48%.
Gross Margin-13.34%
Operating Margin-43910.60%
Pretax Margin-48549.19%
Net Profit Margin-36014.48%
EBITDA Margin-48436.95%
EBIT Margin-48535.61%
Analyst Forecast
The average price target for Paradigm Biopharmaceuticals is $0.66, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$0.66
Price Target Upside56.69% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-20.79%
EPS Growth Forecast73.98%